XML 186 R28.htm IDEA: XBRL DOCUMENT v3.21.2

REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)

6 Months Ended

Jun. 30, 2021

Concentration Risk And Geographic Information [Abstract]

Schedule of Total Revenues from External Customers and Collaborative Partners by Geographic Region

The following table disaggregates Total Revenues from external customers and collaborative partners by geographic region. Net product revenues by geographic region are based on patient location for the Company’s commercial products, except for Aldurazyme, which is sold exclusively to Sanofi Genzyme (Genzyme) who markets and sells Aldurazyme worldwide. Aldurazyme revenues earned by the Company are included in the U.S. region as the transactions are with Genzyme, whose headquarters is located in the U.S.  

			Three Months Ended June 30,												Six Months Ended June 30,
			2021						2020						2021						2020
Total revenues by geographic region:
United States			$	204,245					$	232,552					$	412,431					$	476,724
Europe			172,678						109,259						334,519						254,295
Latin America			42,248						37,864						101,953						97,788
Rest of world			82,522						49,810						138,820						102,747
Total revenues			$	501,693					$	429,485					$	987,723					$	931,554

Schedule of Net Product Revenues by Product

The following table disaggregates total Net Product Revenues by product.

			Three Months Ended June 30,												Six Months Ended June 30,
			2021						2020						2021						2020
Net product revenues by product:
Vimizim			$	171,655					$	116,695					$	329,953					$	253,898
Naglazyme			118,813						81,006						226,149						195,262
Kuvan			78,807						122,611						149,570						244,611
Palynziq			58,935						40,630						112,973						75,262
Brineura			30,332						25,798						57,657						49,768
Firdapse			—						—						—						1,316
Total net product revenues marketed by the Company			$	458,542					$	386,740					$	876,302					$	820,117
Aldurazyme net product revenues marketed by Genzyme			28,128						32,292						$	78,137					$	87,958
Total net product revenues			$	486,670					$	419,032					$	954,439					$	908,075

Schedule of Total Net Product Revenues Based on Patient Location

The table below disaggregates total Net Product Revenues based on patient location for products sold directly by the Company, and global sales of Aldurazyme, which is marketed by Genzyme. 

			Three Months Ended June 30,												Six Months Ended June 30,
			2021						2020						2021						2020
United States			$	169,411					$	197,171					$	324,474					$	378,842
Europe			166,704						104,319						315,576						245,170
Latin America			42,248						37,864						101,953						97,788
Rest of world			80,179						47,386						134,299						98,317
Total net product revenues marketed by the Company			$	458,542					$	386,740					$	876,302					$	820,117
Aldurazyme net product revenues marketed by Genzyme			28,128						32,292						78,137						87,958
Total net product revenues			$	486,670					$	419,032					$	954,439					$	908,075

Schedule of Net Product Revenue Concentrations Attributed to Largest Customers

The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. 

			Three Months Ended June 30,												Six Months Ended June 30,
			2021						2020						2021						2020
Customer A			16		%				15		%				16		%				14		%
Customer B			13		%				16		%				13		%				14		%
Customer C			12		%				4		%				10		%				6		%
Customer D			9		%				13		%				9		%				12		%
Total			50		%				48		%				48		%				46		%

X

- Definition

Concentration risk and geographic information.

+ References

No definition available.

+ Details

Name:	bmrn_ConcentrationRiskAndGeographicInformationAbstract
Namespace Prefix:	bmrn_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph a
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

+ Details

Name:	us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration